title: Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?
abstract: Meaningful progress has been realized in the treatment of metastatic renal cell carcinoma with the recent approval of a number of new agents; more new agents are on the horizon. Despite the recent completion of many clinical trials that have changed or will change practice, many questions remain. In this manuscript, we highlight the most noteworthy developments in the first- and second-line treatment of metastatic renal cell carcinoma, as these are the areas of greatest change. We also emphasize ongoing trials and those areas that are most in need of study in order to move the field forward. Although more data are needed, exciting progress is being made.
authors.affiliation: Duke University Medical Center, Durham, North Carolina.
authors.forename: Bradford R
authors.initials: BR
authors.lastname: Hirsch
authors.affiliation: Duke University Medical Center, Durham, North Carolina.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: George
authors.affiliation: Duke University Medical Center, Durham, North Carolina.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Harrison
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D019233:Retreatment; D059039:Standard of Care; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents